Proven Process Medical Devices Inc., a global manufacturer in the design, development, validation, and manufacture of Class II and Class III medical devices, announced today it has been selected by Giner, Inc. to manufacture its cell implant device for use in administering cell therapies for indications such as liver failure, Parkinson’s disease, (para)thyroid disease, pancreatectomy and Type 1 diabetes (T1D).
Giner, a Boston-based research and development firm committed to developing and commercializing cutting-edge electrochemical technologies, has developed a miniaturized implantable electrochemical oxygen generator (EOG) that will continuously supply oxygen to islets or cells within an immunoisolation cell implant device. Oxygenation maintains cell viability and function at high cellular densities, minimizing overall implant size. The first proposed application of this platform technology is the BioArtificial Pancreas with Implantable Oxygen Supply, or BAPIOS, a human pancreatic islet implant for the treatment of Type 1 diabetes (T1D).
In practice, this bioartificial pancreas includes a remotely powered, miniature oxygen generator that can be implanted in the body and the oxygen produced will be a critical enabler of compact cell therapy implants. The BAPIOS system will be fully implanted subcutaneously without infection-prone percutaneous tubes/leads.
As Giner readies its implantable device for commercialization, it sought a manufacturing partner with deep experience producing intricate, self-contained devices used in the disbursement of various cell therapies. In choosing Proven Process, Giner gains access to the technical acumen of a team well-versed in bringing innovative medical devices from Concept-to-Customer. In addition, Proven Process holds ISO-13485 certification, covering contract services for the design and development, production and servicing of active implantable and in-vitro diagnostic medical devices.